MA26919A1 - 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl-[2,3'] bipyridinyle sous une forme cristalline pure et procede de synthese. - Google Patents

5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl-[2,3'] bipyridinyle sous une forme cristalline pure et procede de synthese.

Info

Publication number
MA26919A1
MA26919A1 MA26971A MA26971A MA26919A1 MA 26919 A1 MA26919 A1 MA 26919A1 MA 26971 A MA26971 A MA 26971A MA 26971 A MA26971 A MA 26971A MA 26919 A1 MA26919 A1 MA 26919A1
Authority
MA
Morocco
Prior art keywords
methanesulfonylphenyl
bipyridinyl
chloro
methyl
crystalline form
Prior art date
Application number
MA26971A
Other languages
English (en)
Inventor
Ian W Davies
Andrew Kotliar
Louis S Crocker
Richard G Osifchin
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22772880&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA26919(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of MA26919A1 publication Critical patent/MA26919A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
MA26971A 2000-05-26 2002-12-23 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl-[2,3'] bipyridinyle sous une forme cristalline pure et procede de synthese. MA26919A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US20801700P 2000-05-26 2000-05-26

Publications (1)

Publication Number Publication Date
MA26919A1 true MA26919A1 (fr) 2004-12-20

Family

ID=22772880

Family Applications (1)

Application Number Title Priority Date Filing Date
MA26971A MA26919A1 (fr) 2000-05-26 2002-12-23 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl-[2,3'] bipyridinyle sous une forme cristalline pure et procede de synthese.

Country Status (49)

Country Link
EP (1) EP1296951B1 (fr)
JP (2) JP3665053B2 (fr)
KR (1) KR100757699B1 (fr)
CN (1) CN1227233C (fr)
AR (1) AR028577A1 (fr)
AT (1) ATE483687T1 (fr)
AU (2) AU6480401A (fr)
BG (1) BG65855B1 (fr)
BR (1) BRPI0111140B8 (fr)
CA (1) CA2410234C (fr)
CR (1) CR6606A (fr)
CY (1) CY1111440T1 (fr)
CZ (1) CZ20023888A3 (fr)
DE (1) DE60143197D1 (fr)
DK (1) DK1296951T3 (fr)
EA (1) EA004809B1 (fr)
EE (1) EE05242B1 (fr)
EG (1) EG24189A (fr)
ES (1) ES2351958T3 (fr)
GC (1) GC0000362A (fr)
GE (1) GEP20053492B (fr)
GT (1) GT200100091A (fr)
HK (1) HK1058932A1 (fr)
HN (1) HN2001000110A (fr)
HR (1) HRP20020934B1 (fr)
HU (1) HU228423B1 (fr)
IL (1) IL152582A0 (fr)
IN (2) IN2002CH02089A (fr)
IS (1) IS2806B (fr)
JO (1) JO2216B1 (fr)
MA (1) MA26919A1 (fr)
ME (1) ME00428B (fr)
MX (1) MX230696B (fr)
MY (1) MY123569A (fr)
NO (1) NO324495B1 (fr)
NZ (1) NZ522394A (fr)
PA (1) PA8516901A1 (fr)
PE (1) PE20011324A1 (fr)
PH (1) PH12001001175B1 (fr)
PL (1) PL358153A1 (fr)
PT (1) PT1296951E (fr)
RS (1) RS51541B (fr)
SI (1) SI1296951T1 (fr)
SK (1) SK287174B6 (fr)
SV (1) SV2002000462A (fr)
TW (1) TWI303634B (fr)
UA (1) UA73355C2 (fr)
WO (1) WO2001092230A1 (fr)
ZA (1) ZA200209558B (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4425514B2 (ja) 1999-11-29 2010-03-03 メルク フロスト カナダ リミテツド ５−クロロ−３−（４−メタンスルホニルフェニル）−６′−メチル−［２，３′］ビピリジニルの多形型、非晶質型および水和型
US6858631B1 (en) 1999-11-29 2005-02-22 Merck & Co., Inc. Polymorphic, amorphous and hydrated forms of 5-chloro-3-(4-methanesulfonylphenyl)-6′-methyl-[2,3′]bipyridinyl
US6521642B2 (en) * 2000-05-26 2003-02-18 Merck & Co., Inc. 5-chloro-3-(4-methanesulfonylphenyl)-6′-methyl-[2,3′]bipyridinyl in pure crystalline form and process for synthesis
HUE028730T2 (en) 2009-02-27 2017-01-30 Cadila Healthcare Ltd Process for the preparation of etoricoxib
WO2012004677A1 (fr) 2010-07-05 2012-01-12 Actavis Group Ptc Ehf Formes à l'état solide de sels d'étoricoxib
PL2714676T3 (pl) 2011-05-27 2019-10-31 Farma Grs D O O Sposób wytwarzania formy polimorficznej I etorykoksybu
EP2773618A1 (fr) 2011-11-03 2014-09-10 Cadila Healthcare Limited Procédé amélioré pour la préparation d'étoricoxibe et de polymorphes de celui-ci
WO2013075732A1 (fr) 2011-11-21 2013-05-30 Synthon Bv Procédé de préparation d'une forme cristalline i de l'étoricoxib
EP2601952A1 (fr) 2011-12-07 2013-06-12 Zentiva, k.s. Nouveaux sels et cocrristaux pharmaceutiqement acceptables du 5- chloro-3-(4-méthanesulfonylphényl)-6'-méthyl-[2,3'] bipyridinyle et leurs utilisations thérapeutiques
EP2888231B1 (fr) 2012-08-27 2019-01-09 Glenmark Pharmaceuticals Limited Procédé de préparation d'étoricoxib cristallin
EP2887924B1 (fr) 2012-08-27 2017-03-29 Cadila Healthcare Limited Compositions pharmaceutiques d'étoricoxib
CN104418799A (zh) * 2013-09-03 2015-03-18 天津药物研究院 一种依托考昔的晶型及其制备方法和应用
WO2015036550A1 (fr) 2013-09-13 2015-03-19 Synthon B.V. Procédé pour la préparation d'étoricoxib
CN106632003B (zh) * 2015-12-31 2019-02-12 上海博志研新药物技术有限公司 一种依托考昔的制备方法
CN108069896B (zh) * 2016-11-11 2022-08-12 昆明积大制药股份有限公司 一种依托考昔晶型的制备方法
CN107056691B (zh) * 2017-06-21 2020-03-10 四川尚锐生物医药有限公司 一种制备依托考昔晶型v的方法
CN107417599B (zh) * 2017-06-21 2020-06-09 四川尚锐生物医药有限公司 一种依托考昔晶型的制备方法
MX2017009660A (es) 2017-07-26 2017-11-23 Laboratorios Liomont S A De C V Composicion farmaceutica con un rango de relacion entre el clorhidrato de tramadol y el etoricoxib para su administracion para el tratamiento del dolor.
CN107556231A (zh) * 2017-09-23 2018-01-09 江苏正大清江制药有限公司 一种依托考昔与对硝基苯甲酸形成的盐的晶型及制备方法
CN107417600A (zh) * 2017-09-26 2017-12-01 江苏正大清江制药有限公司 一种依托考昔与呋喃甲酸形成盐的新晶型及制备方法
CN107898787B (zh) * 2017-12-15 2018-11-30 扬子江药业集团上海海尼药业有限公司 一种药物组合物及其制剂和制备方法
MX2018013070A (es) 2017-12-29 2019-10-15 Gruenenthal Gmbh Combinación farmacéutica que comprende clorhidrato de tramadol de liberación extendida y etoricoxib de liberación inmediata, y su uso para el tratamiento del dolor.
CN110143915A (zh) * 2019-06-03 2019-08-20 蚌埠学院 一种依托考昔与对甲苯磺酸形成盐的新晶型及制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5593994A (en) * 1994-09-29 1997-01-14 The Dupont Merck Pharmaceutical Company Prostaglandin synthase inhibitors
US5739166A (en) * 1994-11-29 1998-04-14 G.D. Searle & Co. Substituted terphenyl compounds for the treatment of inflammation
BRPI9710372B8 (pt) * 1996-07-18 2021-05-25 Merck Canada Inc composto, e, composição farmacêutica.
US5861419A (en) * 1996-07-18 1999-01-19 Merck Frosst Canad, Inc. Substituted pyridines as selective cyclooxygenase-2 inhibitors
PT1071745E (pt) * 1998-04-24 2004-11-30 Merck & Co Inc Processo para sintetizar inibidores cox-2
JP4425514B2 (ja) * 1999-11-29 2010-03-03 メルク フロスト カナダ リミテツド ５−クロロ−３−（４−メタンスルホニルフェニル）−６′−メチル−［２，３′］ビピリジニルの多形型、非晶質型および水和型

Also Published As

Publication number Publication date
JP2004501116A (ja) 2004-01-15
HK1058932A1 (en) 2004-06-11
BRPI0111140B8 (pt) 2021-05-25
NO324495B1 (no) 2007-10-29
ZA200209558B (en) 2003-10-28
EA004809B1 (ru) 2004-08-26
IS2806B (is) 2012-09-15
BG107237A (bg) 2003-05-30
SI1296951T1 (sl) 2011-01-31
AU6480401A (en) 2001-12-11
PE20011324A1 (es) 2002-01-28
EE05242B1 (et) 2009-12-15
KR20030003762A (ko) 2003-01-10
CN1227233C (zh) 2005-11-16
SV2002000462A (es) 2002-03-08
AU2001264804B2 (en) 2006-04-06
SK287174B6 (sk) 2010-02-08
CY1111440T1 (el) 2015-08-05
PL358153A1 (en) 2004-08-09
CA2410234C (fr) 2008-05-13
PT1296951E (pt) 2010-12-07
JP3665053B2 (ja) 2005-06-29
EP1296951B1 (fr) 2010-10-06
SK16702002A3 (sk) 2003-05-02
MX230696B (es) 2005-09-19
CA2410234A1 (fr) 2001-12-06
IL152582A0 (en) 2003-05-29
DE60143197D1 (de) 2010-11-18
JO2216B1 (en) 2004-10-07
CN1443168A (zh) 2003-09-17
CR6606A (es) 2006-02-06
JP4142621B2 (ja) 2008-09-03
EP1296951A1 (fr) 2003-04-02
HUP0302336A2 (hu) 2003-11-28
MY123569A (en) 2006-05-31
PH12001001175B1 (en) 2006-08-10
DK1296951T3 (da) 2011-01-24
NZ522394A (en) 2004-05-28
EG24189A (en) 2008-10-08
ES2351958T3 (es) 2011-02-14
GC0000362A (en) 2007-03-31
IN2002CH02089A (fr) 2005-02-25
IS6630A (is) 2002-11-20
HRP20020934B1 (en) 2012-01-31
PA8516901A1 (es) 2002-04-25
ATE483687T1 (de) 2010-10-15
AR028577A1 (es) 2003-05-14
BRPI0111140B1 (pt) 2018-03-13
TWI303634B (en) 2008-12-01
HN2001000110A (es) 2002-03-06
KR100757699B1 (ko) 2007-09-13
NO20025674L (no) 2002-11-26
NO20025674D0 (no) 2002-11-26
RS51541B (sr) 2011-06-30
EA200201264A1 (ru) 2003-04-24
ME00428B (me) 2011-10-10
EE200200655A (et) 2004-08-16
IN2007CH05103A (fr) 2008-08-27
HRP20020934A2 (en) 2005-02-28
MXPA02011619A (es) 2003-03-27
BR0111140A (pt) 2005-01-11
WO2001092230A1 (fr) 2001-12-06
JP2005047927A (ja) 2005-02-24
BG65855B1 (bg) 2010-03-31
GEP20053492B (en) 2005-04-25
CZ20023888A3 (cs) 2003-02-12
HU228423B1 (en) 2013-03-28
UA73355C2 (en) 2005-07-15
GT200100091A (es) 2001-12-28
YU89402A (sh) 2005-11-28

Similar Documents

Publication Publication Date Title
MA26919A1 (fr) 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl-[2,3'] bipyridinyle sous une forme cristalline pure et procede de synthese.
HK1044945A1 (en) 16-Halogen-epothilone derivatives, method for producing them and their pharmaceutical use.
FR2817865B1 (fr) Derive aminoalkoxybenzoyle sous forme de sel, son procede de preparation et son utilisation comme intermediaire de synthese
HUP0301651A2 (en) Indolylmaleimide derivatives, pharmaceutical compositions containing them, process for producing them and their use
ZA200109859B (en) 6-Alkenyl-, 6-alkinyl- and 6-epoxy-epothilone derivatives, process for their production, and their use in pharmaceutical preparations.
HUP0303109A3 (en) Indolin-2-one derivatives, process for producing them and pharmaceutical compositions containing them
HUP0303568A3 (en) Benzothiophene derivatives, process for their preparation and use thereof
MA25418A1 (fr) Procede pour produire des preparations pharmaceutiques solides rapidement decomposables.
HUP0302295A3 (en) Thienodibenzoazulene derivatives, process for their preparation and use thereof
HUP0202736A3 (en) Substituted aromatic-ring compounds, process for producing the same, and pharmaceutical compositions containing them and use thereof
MXPA01013412A (es) Composiciones de citrato de calcio potasico y metodos de produccion.
ZA200100864B (en) Piperidine-4-sulphonamides compounds, a process for their preparation and pharmaceutical compositions containing them.
HUP0201785A3 (en) Dihydrobenzodiazepins, process for producing them, their use and pharmaceutical compositions containing them
EP1395562A4 (fr) 5-chloro-3-(4-methanesulfonylphenyle)-6'-methyle- 2,3'|bipyridinyle sous forme cristalline pure et procede de synthese
HUP0302429A3 (en) 4-amino-quinazolines, process for producing them, pharmaceutical compositions containing them and their use
HUP0204111A3 (en) Novel process for the preparation of alpha-(2,4-disulfophenyl)-n-tert-butylnitrone and pharmaceutically acceptable salts thereof
HUP0201693A3 (en) Diphosphate salt of a 4"-substituted-9-deoxo-9a-aza-9a-homoerythromycin derivative, process for producing it and its pharmaceutical composition
HUP9900263A3 (en) 11-acetyl-12,13-dioxabicyclo[8.2.1.]tridecenon derivatives, process for producing them and pharmaceutical compositions containing them
ZA200101340B (en) 6-amino or 6-hydrazino-sulphonyl-3-quinolinylphosphonic acid compounds, a process for their preparation and pharmaceutical composition containing them.
ZA200103065B (en) Heterocycloalkylbenzocyclobutane and heteroarylbenzocyclobutane compounds, a process for their preparation and pharmaceutical compositions containing them.
IL128738A0 (en) Magnesium and potassium double salts, process for their preparation and uses thereof
HUP0002147A3 (en) Hydroxybenzoic acid derivatives, process for producing them and pharmaceutical compositions having antiplasmid activity comprising the said compounds
SI1250320T1 (en) Novel process for the preparation of alpha-(2,4-disulfophenyl)-n-tert-butylnitrone and pharmaceutically acceptable salts thereof
HU0101504D0 (en) New cyclobutaindolecarboxamide derivatives, process for their preparation and pharmaceutical compositions containing them
HK1052709A1 (en) Pluraflavins and derivatives thereof, process for their preparation and use thereof pluraflavin.